Appeals Court Rejects False Claims Approach To FDA Off-Label Cases
Executive Summary
A ruling from the First Circuit suggests that plaintiffs can’t prove manufacturers violated the False Claims Act by suggesting FDA submissions were fraudulent, if FDA itself hasn’t taken any action against the manufacturer.
You may also be interested in...
Medtronic Biz Pleads Guilty In Off-Label Marketing Case
A Medtronic subsidiary has agreed to plead guilty for off-label marketing activities that occurred prior to Medtronic's acquisition. Overall, the firm says it has settled three investigations with a total pay-out of $50.9m. US FDA is underscoring the case as an example of the agency pursuing companies that "put profit over safety."
Unlocking Legalities: Ninth Circuit Allows Wider Range Of False Claim Suits
The Ninth Circuit Court of Appeals allowed False Claims Act allegations against drug manufacturers Gilead Sciences to move forward despite a US Supreme Court ruling last year that raised FCA standards.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.